Epidemiology and risk factors for healthcare-associated infections caused by Pseudomonas aeruginosa

References

• Athanasiou CI, Kopsini A. Systematic review of the use of time series data in the study of antimicrobial consumption and Pseudomonas aeruginosa resistance. J Glob Antimicrob Resist. 2018;15:69–73.
   PubMed Web of Science ®Google Scholar
• Rosenthal VD, Maki DG, Mehta Y, Leblebicioglu H, Memish ZA, Al-Mousa HH, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 43 countries for 2007–2012. Device-associated module [published correction appears in Am J Infect Control. 2015;43(7):779–81]. Am J Infect Control. 2014;42(9):942–56.
   PubMed Web of Science ®Google Scholar
• Gupta R, Malik A, Rizvi M, Ahmed SM. Incidence of multidrug-resistant Pseudomonas spp. in ICU patients with special reference to ESBL, AMPC, MBL and biofilm production. J Glob Infect Dis. 2016;8(1):25–31.
   PubMed Web of Science ®Google Scholar
• Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. J Med Microbiol. 2014;63(Pt 12):1679–87.
   PubMed Web of Science ®Google Scholar
• Merchant S, Proudfoot EM, Quadri HN, McElroy HJ, Wright WR, Gupta A, et al. Risk factors for Pseudomonas aeruginosa infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: a systematic literature review and meta-analysis. J Glob Antimicrob Resist. 2018;14:33–44.
   PubMed Web of Science ®Google Scholar
• Peng Y, Bi J, Shi J, Li Y, Ye X, Chen X, et al. Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to healthcare-associated infection control in the hospitals of Southern China: a case-control surveillance study. Am J Infect Control. 2014; 42(12):1308–11.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li X, Li W, Du X, He J-Q, Tao C, et al. Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis. Sci Rep. 2015;5(1):11715.
   PubMedGoogle Scholar
• Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control. 1988;16(3):128–40.
   PubMed Web of Science ®Google Scholar
• Kiska DL, Gilligan PH. Pseudomonas and Burkholderia. In: Murray PR, Baron EJ, Pfaller MA, editors. Manual of clinical microbiology. Washington (DC): American Society for Microbiology; 1995. p. 517–25.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-eighth informational supplement (M100-S28). Wayne (PA): Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.
   PubMed Web of Science ®Google Scholar
• Sun Y, Deng Y, Kwapong WR, Ma L. Clinical distribution, drug resistance and risk factor analysis of Pseudomonas aeruginosa infections. Int J Clin Exp Med. 2019;12(10):12322–30.
   Web of Science ®Google Scholar
• Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(5):1983–6.
   PubMed Web of Science ®Google Scholar
• Voor In ‘t Holt AF, Severin JA, Lesaffre EM, Vos MC. A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2014;58(5):2626–37.
   PubMed Web of Science ®Google Scholar
• Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay J-P, Bilocq F, et al. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of intensive care unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents. 2010;36(6):513–22.
   PubMed Web of Science ®Google Scholar
• Japoni A, Alborzi A, Kalani M, Nasiri J, Hayati M, Farshad S. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Burns. 2006;32(3):343–7.
   PubMed Web of Science ®Google Scholar
• Gunn JS, Ryan SS, Van Velkinburgh JC, Ernst RK, Miller SI. Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar Typhimurium. Infect Immun. 2000;68(11):6139–46.
   PubMed Web of Science ®Google Scholar
• Venier A-G, Leroyer C, Slekovec C, Talon D, Bertrand X, Parer S, et al. Risk factors for Pseudomonas aeruginosa acquisition in intensive care units: a prospective multicentre study. J Hosp Infect. 2014;88(2):103–8.
   PubMed Web of Science ®Google Scholar
• Raman G, Avendano EE, Chan J, Merchant S, Puzniak L. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2018;7:79.
   PubMed Web of Science ®Google Scholar
• Ponce de Leon A, Merchant S, Raman G, Avendano E, Chan J, Tepichin Hernandez G, et al. Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):250.
   PubMed Web of Science ®Google Scholar
• Bagge N, Schuster M, Hentzer M, Ciofu O, Givskov M, Greenberg EP, et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production. Antimicrob Agents Chemother. 2004;48(4):1175–87.
   PubMed Web of Science ®Google Scholar
• Harris AD, Jackson SS, Robinson G, Pineles L, Leekha S, Thom KA, et al. Pseudomonas aeruginosa colonization in the intensive care unit: prevalence, risk factors, and clinical outcomes. Infect Control Hosp Epidemiol. 2016;37(5):544–8.
   PubMed Web of Science ®Google Scholar
• Abbara S, Pitsch A, Jochmans S, Hodjat K, Cherrier P, Monchi M, et al. Impact of a multimodal strategy combining a new standard of care and restriction of carbapenems, fluoroquinolones and cephalosporins on antibiotic consumption and resistance of Pseudomonas aeruginosa in a French intensive care unit. Int J Antimicrob Agents. 2019;53(4):416–22.
   PubMed Web of Science ®Google Scholar
• Raman G, Avendano E, Berger S, Menon V. Appropriate initial antibiotic therapy in hospitalized patients with Gram-negative infections: systematic review and meta-analysis. BMC Infect Dis. 2015;15:395.
   PubMed Web of Science ®Google Scholar
• Maraolo AE, Cascella M, Corcione S, Cuomo A, Nappa S, Borgia G, et al. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art. Expert Rev Anti Infect Ther. 2017;15(9):861–71.
   PubMed Web of Science ®Google Scholar